ArticleCanadian family physician Medecin de famille canadien2026
Increasing prescribing of acetylsalicylic acid in pregnancy: Program evaluation in Saskatchewan.
Article in Canadian family physician Medecin de famille canadien, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the proportion of patients with a singleton pregnancy who are at risk for preeclampsia, based on a Society of Obstetricians and Gynaecologists of Canada guideline that reclassified a body mass index value greater than 30 kg/m
designA pre-post study evaluated prescribing of preventive ASA for patients at risk for preeclampsia, as documented in electronic medical records (EMRs) before and after a lunch-and-learn session.
settingTwo private family medicine clinics located in a regional centre in Saskatchewan.
participantsThe EMRs of all patients with a singleton pregnancy who received care at either of the 2 participating clinics between January 1 and March 31, 2023 (pre-intervention period) or between February 1 and April 30, 2024 (post-intervention period) were retrospectively reviewed.
main outcome measuresThe proportion of patients at risk for preeclampsia, and the proportion of those patients who were prescribed prophylactic ASA.
resultsOf the 119 patients evaluated, 95 had sufficient information to determine their risk status, of whom 46 (48%) were at increased risk for preeclampsia. ASA use increased statistically significantly among at-risk patients after the educational session; 2 of 29 (7%) patients received ASA before and 6 of 17 (35%) after the intervention (odds ratio=5.8; 95% confidence interval 2.2 to 15.7). More than 85% of patients in both intervention periods presented before 16 weeks' gestation, the recommended time for ASA initiation.
conclusionApproximately half of the patients with singleton pregnancies in the community were eligible for ASA prophylaxis. Family physicians who provide early prenatal care and see patients during the optimal time for initiating prophylaxis with ASA infrequently provide this preventive treatment. A single educational session increased physicians' ASA prescription rates, but additional strategies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.